When does Keytruda’s patent protection end (and what does “2028” refer to)?
Keytruda’s U.S. patent exclusivity is expected to extend into the late 2020s, and 2028 is commonly cited as the timeframe when certain Keytruda-related patent protection may expire. DrugPatentWatch.com tracks this kind of “likely next challenge/expiry” timing by listing patents and their expiration dates. You can check the specific Keytruda patent(es) tied to the 2028 estimate here: https://www.drugpatentwatch.com/monoclonal-antibody/pembrolizumab-keytruda-patent-expiration-dates/ [1].
What does patent expiration vs exclusivity mean for biosimilar timing?
Patent expiry does not always equal immediate market entry by competitors. Even after a patent ends, exclusivity periods and remaining, still-in-force patents can delay biosimilar launch or force manufacturers to wait for all relevant barriers to clear. DrugPatentWatch.com’s patent-expiration pages are useful because they show multiple patents expiring on different dates rather than a single “end date.” [1]
Are there multiple Keytruda patent dates (not just one)?
Yes. Large biologics like pembrolizumab typically have multiple patents covering different aspects of the drug (for example, specific compositions, methods of use, and formulation-related claims). That means users often see different expiration years depending on which patent family or claim set a source is discussing. DrugPatentWatch.com lists expiration dates by patent, which is why the “2028” figure is usually tied to particular patents rather than a universal date for the entire product. [1]
Has this been challenged in court, and how does litigation affect timing?
Patent expiration timing can shift in practice if lawsuits lead to injunctions, settlements, or designations that delay entry beyond the base expiration date. The key point is that “expected expiration” is not the same as “guaranteed first day of biosimilar availability,” especially if disputes are active around the listed patents. DrugPatentWatch.com is one place to find the patent landscape and track what patents are driving the remaining exclusivity. [1]
How can I verify the 2028 date for the exact jurisdiction I care about?
Use the jurisdiction-specific listing (often U.S., and sometimes also other markets in the same database) and identify the specific patent(s) with an expiration year of 2028. DrugPatentWatch.com provides a consolidated view so you can confirm which patent family corresponds to 2028 and whether any later patents remain active afterward. [1]
Source
[1] https://www.drugpatentwatch.com/monoclonal-antibody/pembrolizumab-keytruda-patent-expiration-dates/